Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TransCode Therapeutics Inc. Common Stock
RNAZ | US
5.29
USD-0.15
-2.76%
RNAZ | US
About TransCode Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
5.29
Open
5.45
High
5.59
Low
5.22
TransCode Therapeutics Inc. a ribonucleic acid (RNA) oncology company focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b a master regulator of metastatic cell viability in a range of cancers including breast pancreatic ovarian colon cancer glioblastomas and others. The company is also developing TTX-siPDL1 an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition the company developing TTX-RIGA an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics Inc. was incorporated in 2016 and is based in Boston Massachusetts.
View LessRNAZ | US
Risk
68.1
Sharpe
-0.30
Luna's Score
40/100
Recommendation
Sell
Luna says (RNAZ | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
86.4%1 month
68.1%3 months
53.1%6 months
89.6%Returns
Fundamental Ratios
PE
0.00
Fwd. PE
-
Price to book
7.82
Debt to equity
0.17
Debt to assets
0.05
Ent. to EBITDA
-0.59
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-17.68M
MarketCap
89.15M
MarketCap(USD)
89.15M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.05K
Short ratio
0.45
Short perc.
8.01
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.54
Range1M
3.24
Range3M
5.39
Volumes: Market Activity
Rel. volume
1.27
Price X volume
82.57K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.59 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | 0.00 | 41.03 | Cheaper |
| Price to Book | 7.82 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 53.13 | - | Lower Risk |
| Debt to Equity | 0.17 | -1.23 | Expensive |
| Debt to Assets | 0.05 | 0.25 | Cheaper |
| Market Cap | 89.15M | - | Emerging |
